Evidence map›Paper›PMID 41995838›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Ternary classification prediction and heterogeneity quantification for HER2-Zero, -low, and -positive in breast cancer using HER2-targeted PET/CT imaging.

Yuan Gao, Lei Yin, Xiaojiang Duan, Qian Liu, Xiaojuan Zhu, Caixia Wu, Ling Xin, Jinzhi Chen, Li Liang, Ling Xu and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuan Gao *Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Lei Yin *Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Xiaojiang DuanDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Qian LiuThyroid and Breast Surgery, Peking University First Hospital, Beijing, China.
Xiaojuan ZhuDepartment of Pathology, Peking University First Hospital, Beijing, China.
Caixia WuDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Ling XinThyroid and Breast Surgery, Peking University First Hospital, Beijing, China.
Jinzhi ChenDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Li LiangDepartment of Pathology, Peking University First Hospital, Beijing, China.
Ling XuThyroid and Breast Surgery, Peking University First Hospital, Beijing, China.
Jingming YeThyroid and Breast Surgery, Peking University First Hospital, Beijing, China. md_ye@sina.com.ORCID http://orcid.org/0009-0007-5740-0602
Hongfeng LiInstitute of Medical Technology, Peking University Health Science Center, Beijing, China. hongfel3@pku.edu.cn.ORCID http://orcid.org/0000-0003-4589-3116
Meng LiuDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, China. louisa_liu@bjmu.edu.cn.ORCID http://orcid.org/0000-0002-6960-3163

Funding

Beijing Natural Science Foundation Z210007National Natural Science Foundation of China 82172052Youth Clinical Research Special Fund Project of Peking University First Hospital 2025YC-GD06
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

68Ga-HER2-affibody PET/CTAntibody-drug conjugates (ADCs)Breast cancerHabitat analysisRadiomics

Identifiers

PMID41995838

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.